



## **Kalytera Therapeutics Inc.**

### **Name Change to *Claritas Pharmaceuticals, Inc.***

**SAN FRANCISCO, CA and TORONTO, ON -- (April 8, 2021)** – Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE (TSXV): KLY and OTC: KALTF) (the “**Company**” or “**Kalytera**”) today announced that the Company is changing its name to Claritas Pharmaceuticals, Inc. The name change will become effective and the common shares of the Company will begin trading under the new name effective on April 12, 2021. The name change is subject to final TSX Venture Exchange (“TSXV”) approval.

#### About the Name Change

The decision to rename the Company signals the re-launch of the Company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 as well as other viral infections. R-107 is a nitric oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the viruses that cause influenza and the common cold.

The Company’s ticker symbol will change as a result of the name change. Effective April 12, 2021, the new ticker symbol will be CLAS.

Shareholders will receive letters of transmittal from the Company’s transfer agent, which will also be posted on SEDAR, and which can be used to exchange their current share certificates for certificates with the Company’s new name. Shareholders holding shares in electronic form need not take any action. All shareholders should refer to the letter of transmittal and instructions from their broker/dealer.

The Company’s new CUSIP, ISIN numbers and ticker symbols for the Company’s active listed securities under its new name are:

- Common shares: ISIN: CA1806341071; CUSIP: 180634107; Ticker Symbol: CLAS
- Warrants designated as WT: ISIN: CA1806341154 ; CUSIP: 180634115; Ticker Symbol: CLAS.WT.A
- Warrants designated as WTS22: ISIN: CA1806341238; CUSIP: 180634123; Ticker Symbol: CLAS.WT.B

#### **About Claritas Pharmaceuticals**

Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives.

- Website Home: <https://claritaspharma.com/>
- News and Insights: <https://claritaspharma.com/news/>
- Investors: <https://claritaspharma.com/investors/>

#### **Cautionary Statements**

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives, and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavorable results. Claritas undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Claritas believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Claritas' control. The company's name change has not yet been affected and the company believes that it will affect the name change subject to regulatory compliance as soon as practicable after this news release. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.*

**Contact Information**

Robert Farrell

President, CEO

(888) 861-2008

[info@claritaspharma.com](mailto:info@claritaspharma.com)